Lakeside Acquires Hupan Pharmaceutical, Enters China’s Medical Logistics Market

• Lakeside acquires Hupan Pharmaceutical, securing entry into China’s medical logistics sector.

• The acquisition is expected to generate $7 million in additional revenue annually.

Lakeside Holding Limited, a cross-border supply chain solutions provider focusing on the Asian market, has acquired Hupan Pharmaceutical (Hubei) Co., Ltd.

Lakeside announced its acquisition of Hupan Pharmaceutical for RMB 4.0 million (approximately $0.6 million USD) through its subsidiary Sichuan Hupan. This acquisition marks Lakeside’s entry into the medical logistics industry in China. Hupan Pharmaceutical specialises in pharmaceutical distribution and supply chain services, offering Lakeside access to a broader healthcare market.

Based in Wuhan, China, Hupan Pharmaceutical serves a range of healthcare institutions in Hubei province, including partnerships with Sinopharm Group Hubei Co., Ltd., a subsidiary of the prominent Sinopharm Holding, which holds a major position in the Chinese pharmaceutical industry. The acquisition was announced this week, with the transaction expected to contribute $7 million in revenue annually.

Henry Liu, Chairman and CEO of Lakeside, stated that the acquisition provides “an important foothold” for Lakeside in the medical logistics field, enhancing their logistics and supply chain offerings within China’s pharmaceutical market.